Neurogene Inc.

Neurogene Inc.

NGNE·NASDAQ

$26.22

+0.31%
HealthcareBiotechnology

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

At a Glance

Live Snapshot
Market Cap$414.33M
EPS-4.2400
P/E Ratio-6.18
Earnings Date08/07/2026

ngne

Other Receivables

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Neurogene Inc.

Neurogene Inc. Competitors Analysis of Other Receivables

NGNE · NASDAQ
CompanyOther Receivables
CAGR 3Y
CAGR 5Y
CAGR 10Y
NGNE logo
Neurogene Inc.
NASDAQ:NGNE
0.00
N/AN/AN/A 
OCGN logo
Ocugen, Inc.
NASDAQ:OCGN
0.00
N/AN/AN/A
2.08M
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
177.00K
N/AN/AN/A
2.12M
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
6.37M
N/A72.7%N/A
1.07M
-14.5%17.7%N/A
Neurogene Inc.

Neurogene Inc. Fair Value Envelope

NGNE · NASDAQ

Our analysis suggests that NGNE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $26.22, this represents a potential HIDDEN relative to our calculated worth for Neurogene Inc..

Intrinsic Value
Current Price: $26.22